Third-generation antibody drug conjugates for cancer therapy--a balancing act. (2016)
Attributed to:
Improving the functional affinity of human anti-glycan monoclonal antibodies (mabs) for cancer therapy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.4155/tde-2016-0002
PubMed Identifier: 26893243
Publication URI: http://europepmc.org/abstract/MED/26893243
Type: Journal Article/Review
Volume: 7
Parent Publication: Therapeutic delivery
Issue: 3
ISSN: 2041-5990